Dog /

Breed profile · FDA CVM July 2026 extract

Dalmatian adverse-event record

Adverse-event filings for Dalmatian (Dog) in the FDA Center for Veterinary Medicine openFDA extract. Browse dog breeds, reactions, and outcomes below.

#93 of 510
by report volume (all breeds)
1,356
FDA CVM reports on file
4.6%
death-coded share of reports
#150 of 275
by death-coded share (≥50 reports)

How the 1,356 reports break down

By recorded gender -- every report on file for Dalmatian, no filtering.

Annual report volume

Annual adverse-event report trend Yearly FDA CVM adverse-event report counts for this breed. 88 66 44 22 0 2019 2020 2021 2022 2023 2024 2025 2026 Reports filed Death-coded reports
Annual report volume for Dalmatian drawn from FDA CVM filings.

Data updated September 2026

The verdict

According to the FDA Center for Veterinary Medicine openFDA adverse-event extract, Dalmatian ranks #93 of 510 by total reports (1,356) and #150 of 275 by death-coded share (4.6%). National dual: Retriever - Labrador is #1 of 510 by total adverse-event reports (93,675) at death-coded-share rank 195 of 275 breeds with at least 50 reports (3.7%); separately, Atlantic Salmon (Salmo salar) is #1 highest death-coded share at 99.0% (report rank #233).

93,675
Retriever - Labrador reports (#1)
99.0%
Atlantic Salmon (Salmo salar) death share (#1)
#93
This breed, reports of 510
#150
This breed, death share of 275

Report volume reflects how common a breed or drug is and how often owners and vets file — not actual risk. Death-coded share ranks are limited to entries with enough reports to be meaningful. The two maps do not agree at #1.

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Dalmatian has 1,356 reports now versus 1,342 in that prior snapshot: 14 more (1.0%).

Report change
+14
Death-coded reports
+0
Death-coded share
−0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Dalmatian changes

Total Reports

1,356

High report volume

Deaths Reported

62

of 1,356 reports

Death-coded share of reports

4.6%

Below-median death-coded share

Avg Age at Report

5.7 yr

25.2 kg avg weight

Breed Safety Scorecard

C- (51/100)

A weighted composite across 4 of 4 dimensions, each benchmarked against every tracked breed with at least 200 reports (n=185). Dimensions with insufficient data drop out and their weight redistributes to the rest, so a missing input never silently deflates the score.

Death rate D
4.6%

Share of reports coded as a fatality

Euthanasia rate B-
1.8%

Share of reports resulting in euthanasia

Full recovery rate C-
29.2%

Share of reports coded "Recovered/Normal"

5-year trend F
+26%

Change in annual report volume over the last 5 complete years

Death-Coded Outcome Share

Dalmatian death-coded reports 4.6%
Cross-breed median

4.6% of 1,356 dalmatian reports involved a death outcome.

How to read this number

Read alongside breed popularity, veterinary access, and owner awareness, these shape how many events ever reach the FDA. The comparison line marks the cross-breed median death-coded share (4.8%) among breeds with 50 or more reports; values above it suggest higher reporting bias toward severe outcomes, not necessarily higher true mortality.

Where Dalmatian's death-coded share sits among indexed breeds

Death-coded share of FDA CVM reports, breeds with ≥50 reports (July 2026 extract)

5% 45th percentile Higher share than 45% of 275 indexed breeds

5%–10%: 1 indexed breeds (0%). This entry sits in this band. 20%–25%: 2 indexed breeds (1%). Above this entry. 25%–30%: 3 indexed breeds (1%). Above this entry. 30%–35%: 4 indexed breeds (1%). Above this entry. 35%–40%: 5 indexed breeds (2%). Above this entry. 40%–45%: 6 indexed breeds (2%). Above this entry. 45%–50%: 3 indexed breeds (1%). Above this entry. 50%–55%: 7 indexed breeds (3%). Above this entry. 55%–60%: 7 indexed breeds (3%). Above this entry. 60%–65%: 21 indexed breeds (8%). Above this entry. 65%–70%: 11 indexed breeds (4%). Above this entry. 70%–75%: 15 indexed breeds (5%). Above this entry. 75%–80%: 13 indexed breeds (5%). Above this entry. 80%–85%: 11 indexed breeds (4%). Above this entry. 85%–90%: 12 indexed breeds (4%). Above this entry. 90%–95%: 12 indexed breeds (4%). Above this entry. 95%–100%: 142 indexed breeds (52%). Above this entry. Dalmatian 5% 100% every breed with ≥50 FDA reports, bucketed by value

Each bar is a band; taller bars hold more indexed breeds. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source FDA Center for Veterinary Medicine, openFDA adverse event extract (PlainBreed) · July 2026 extract

This histogram uses the same ≥50-report cohort as the highest death-coded share ranking. A higher share means more of this breed's reported events were death-coded, not a mortality rate for living animals.

Average weight at time of report: 25.2 kg (55.6 lbs)

Top Reported Reactions

Vomiting 262
Diarrhoea 110
Emesis 106
Lack of efficacy - NOS 94
Lethargy (see also Central nervous system depression in 'Neurological') 88
Lack of efficacy (ectoparasite) - flea 80
Lack of efficacy (endoparasite) - heartworm 77
Lack of efficacy (endoparasite) - hookworm 73
INEFFECTIVE, HEARTWORM LARVAE 69
Digestive tract disorder NOS 48
Seizure NOS 47
Anorexia 41
Ataxia 40
Other abnormal test result NOS 37
Behavioural disorder NOS 36

Most Referenced Drugs

Milbemycin Oxime + Spinosad 264
Ivermectin + Pyrantel As Pamoate Salt 152
Afoxolaner 88
Pyrantel Pamoate;Sarolaner 81
Spinosad 80
Moxidectin 74
Milbemycin Oxime + Praziquantel 55
Oclacitinib Maleate 48
Carprofen 42
Trilostane 42
Fluralaner Chew Tablets 41
Bedinvetmab 35
Sarolaner 31
Fluralaner 13.64% 12-Week Chew 29
Gabapentin 23

Outcome Breakdown

Outcome Unknown
438 (34.8%)
Recovered/Normal
396 (31.5%)
Ongoing
307 (24.4%)
Recovered with Sequela
56 (4.4%)
Died
38 (3.0%)
Euthanized
24 (1.9%)

Gender Distribution

Female 722 (53.2%)
Male 592 (43.7%)
Unknown 38 (2.8%)
Mixed 4 (0.3%)

Reports by Year

Year Reports Trend
2010 52
2011 73
2012 100
2013 89
2014 99
2015 112
2016 100
2017 102
2018 86
2019 75
2020 88
2021 62
2022 61
2023 83
2024 86
2025 78
2026 10

Dalmatian: high-volume FDA adverse-event cohort

Signature read: 1,356 reports place Dalmatian in the upper third of breed filing volume (#93 of 510). According to FDA CVM filings indexed on PlainBreed as of July 2026 extract, Dalmatian sits at #93 of 510 by report volume among all breeds and #77 of 298 among dog breeds, with 1,356 reports and 62 (4.6%) death-coded. On death-coded share among breeds with ≥50 reports, it ranks #150 of 275. Mean age at report: 5.7 years, average weight 25.2 kg (55.6 lbs).

Top reported signs: Vomiting (262), Diarrhoea (110), Emesis (106). Most-referenced drug: Milbemycin Oxime + Spinosad (264 reports), followed by Ivermectin + Pyrantel As Pamoate Salt (152) and Afoxolaner (88).

Outcome coding on 1,259 status-recorded reports is dominated by Outcome Unknown (34.8%). Annual submissions ranged 10-2,026 across 17 years on file.

Dog Breeds With a Similar Report Volume

Showing 6 of 297 dog breeds in our dataset, ranked by closest report volume.

Nationwide breeds with similar profiles

High-volume peer sets for Dalmatian drawn from openFDA outside the Dog family so the neighborhoods are not species containment (the similar-volume list above stays within species).

Similar death-coded share

Nearest other-species breeds with ≥50 reports (4.6% death-coded here).

Similar average weight

Nearest other-species breeds by reported average weight (25.2 kg here).

What to do with this dog

A report does not prove a drug caused the reaction, and popular breeds simply generate more reports.

Frequently Asked Questions

How many FDA adverse event reports involve Dalmatian?
There are 1,356 adverse event reports involving Dalmatian in the FDA database, of which 62 were death-coded (4.6% of those reports). That is a share of REPORTED events, not a mortality rate for the breed: adverse events reach the FDA when something goes wrong, so the denominator is reports, never the population of animals. According to the same FDA CVM extract, Dalmatian ranks #93 of 510 by report volume among all breeds PlainBreed indexes (#77 of 298 among dog breeds).
Where does Dalmatian sit among other breeds in PlainBreed's corpus?
According to FDA CVM report volume, Dalmatian is #93 of 510 breeds indexed on PlainBreed (same ordering as the most-reported-breeds ranking). Inside Dog, it is #77 of 298. Among breeds with at least 50 reports, its death-coded share ranks #150 of 275 (same cohort as highest-death-rate). These are placement ranks in the reporting corpus, not clinical risk scores.
What are the most common adverse reactions reported for Dalmatian?
The most commonly reported adverse reactions for Dalmatian are Vomiting (262 reports), Diarrhoea (110 reports), Emesis (106 reports), Lack of efficacy - NOS (94 reports), Lethargy (see also Central nervous system depression in 'Neurological') (88 reports).
What drugs are most frequently associated with Dalmatian adverse events?
The drugs most frequently referenced in Dalmatian adverse event reports are Milbemycin Oxime + Spinosad (264 reports), Ivermectin + Pyrantel As Pamoate Salt (152 reports), Afoxolaner (88 reports), Pyrantel Pamoate;Sarolaner (81 reports), Spinosad (80 reports).
What is the average age of Dalmatian in adverse event reports?
The average age of Dalmatian at the time of adverse event reports is 5.7 years, with an average weight of 25.2 kg (55.6 lbs).

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Dalmatian (Dog), extract as of July 2026 extract. 1,356 reports · 62 death-coded (4.6% of reports, not a mortality rate) · #93 of 510 by volume.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →